Mylan Laboratories Appoints Michael Marquard President of Mylan Bertek Pharmaceuticals

PITTSBURGH, June 22 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced the appointment of Michael Marquard as Vice President of Mylan Laboratories Inc. and President of Mylan's branded subsidiary, Mylan Bertek Pharmaceuticals Inc. Mr. Marquard joins Mylan from Wyeth, where he has been the Senior Vice President of U.S. Sales since 1996, and a member of the U.S. management team and Wyeth's Pharmaceutical business unit global leadership team.

Mr. Marquard has over 30 years of experience in the pharmaceuticals industry and brings to Mylan Bertek an extensive background in the launch, sales and marketing of proprietary products and the management of branded businesses. He served most recently with Wyeth, where he was responsible for managing the 3,700-person sales force of Wyeth's Pharmaceuticals business unit. From 1973 to 1995, Mr. Marquard held a variety of positions at American Cyanamid Company, a business that eventually merged with Wyeth. His positions at American Cyanamid included: Vice President and General Manager, Lederle Pharmaceuticals; Vice President and General Manager, Lederle Oncology; and Vice President, Sales, Lederle Laboratories. Over the course of his career, Mr. Marquard has managed more than 10 major product launches in a variety of therapeutic categories, with particular emphasis in the cardiovascular arena. Some of the key cardiovascular products he has launched include Maxzide®, Altace®, Ziac®, Verelan® and Cordarone IV®. Drugs in other therapeutic categories include Zosyn®, a hospital antibiotic, and Enbrel® for rheumatoid arthritis.

"The depth and breadth of Michael's experience speak for themselves," said Robert J. Coury, Vice Chairman and Chief Executive Officer of Mylan Laboratories. "We are confident that he will be an important driver of our continued commitment to further building our brand franchise and the creation of a well balanced pharmaceutical company. His leadership and expertise in launching new products will be particularly valuable in helping us to assure a successful launch of nebivolol upon its approval by the FDA, and to capitalize on other exciting opportunities which lie ahead for Mylan Bertek."

"I was attracted to this position at Mylan Bertek because it offers a unique entrepreneurial opportunity within an already established, leading pharmaceutical company," said Michael Marquard. "With the momentum of two proprietary products coming through the pipeline -- the launch of APOKYN™ and nebivolol's New Drug Application pending at the Food and Drug Administration, this is truly an exciting time to be joining this company."

Mr. Marquard, who will join the company on July 6, replaces Mylan Bertek's current President, James Mauzey, who is retiring from the company, effective June 30. Mr. Mauzey joined Mylan in 2000 and assisted in the development of Bertek and its sales force.

Mr. Coury continued: "We thank Jim for his contributions to Bertek over the last four years and wish him all the best in his retirement."

Mylan Bertek Pharmaceuticals Inc., based in Research Triangle Park, N.C., develops and licenses proprietary pharmaceuticals, with a current focus on dermatology, neurology and cardiology. For more information, visit www.bertek.com .

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories, Inc. and Mylan Bertek Pharmaceuticals Inc., that develop, manufacture and market an extensive line of generic and proprietary products.

For more information about Mylan, visit www.mylan.com .

This press release includes statements that constitute "forward-looking statements", including with regard to the launch of nebivolol and APOKYN, as well as Mr. Marquard's affiliation with the Company. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: risks that nebivolol will not receive marketing approval or that it may not ultimately prove to be successful as an important therapy for hypertensive patients; delays in the launch of APOKYN, including due to matters outside of the Company's control; the Company's exposure to lawsuits, regulatory delays or contingencies associated with its business; uncertainties regarding market acceptance of and demand for the products; and the other risks detailed in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release. Product names mentioned herein may be trademarks and/or registered trademarks of their respective owners.

SOURCE Mylan Laboratories Inc.

06/22/2004
CONTACT: (Media) Heather Bresch, +1-724-514-1800
or (Investors) Kris King +1-724-514-1800
both of Mylan Laboratories Inc.
Web site: http://www.mylan.com
http://www.bertek.com